Optimi Health (OPTI) investor relations material

Company overview and business model

• Canadian GMP-compliant pharmaceutical manufacturer specializing in MDMA and psilocybin from botanical sources, licensed by Health Canada for controlled substances.

• Vertically integrated with two 10,000 sq. ft. production facilities in Princeton, BC, supporting cultivation, extraction, formulation, and distribution.

• Products are available in Australia (prescription for TRD and PTSD) and Canada (Special Access Program); expansion planned for Israel and the U.S.

• Holds Drug Establishment Licence (DEL), Dealer's Licence (DL), and Precursor Licence, enabling legal manufacture and export of psychedelic drugs.

• Focused on scaling pharmaceutical-grade manufacturing, winding down nutraceutical business.

Financial performance and metrics

• Fiscal year ended September 30, 2025: revenue C$426,301 (US$306,097), net loss C$3,712,031 (US$2,665,349), accumulated deficit C$27,241,680.

• Three months ended December 31, 2025: revenue C$232,700, net loss C$1,553,975.

• Cash and cash equivalents as of December 31, 2025: C$491,750; total assets C$14,236,203; total liabilities C$9,219,190.

• Company has a history of operating losses and recurring negative cash flows; going concern risk disclosed.

Use of proceeds and capital allocation

• Net proceeds of approximately US$12.2 million (or US$14.3 million if over-allotment exercised) expected from the offering.

• 28.7% for scaling production and distribution in current markets, 18.0% for market entry to Israel and the U.S., 53.3% for working capital and operating expenses.

• Management has broad discretion over use of proceeds; additional funds may be needed for U.S. market entry beyond 12 months.